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Abstract: Ghrelin, a gastrointestinal peptide with a major role in regulating feeding and 
metabolism, has recently been investigated for its neuroprotective effects. In this review we 
discuss pre-clinical evidence suggesting ghrelin may be a useful therapeutic in protecting 
the brain against injury after ischemic stroke. Specifically, we will discuss evidence 
showing ghrelin administration can improve neuronal cell survival in animal models of 
focal cerebral ischemia, as well as rescue memory deficits. We will also discuss its 
proposed mechanisms of action, including anti-apoptotic and anti-inflammatory effects, 
and suggest ghrelin treatment may be a useful intervention after stroke in the clinic.  
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1. Introduction 
The search for neuroprotective treatments after ischemic brain injury has so far proved remarkably 
unsuccessful. Indeed, recombinant tissue plasminogen activator (rt-PA), first introduced in the  
1980s [1], is currently the only useful treatment for ischemic stroke. Although rt-PA effectively 
restores blood flow to the brain it cannot directly target the fundamental mechanisms of ischemic 
injury. Furthermore, owing to the narrow therapeutic window (less than 4.5 h), only a small proportion 
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of stroke patients actually receive rt-PA [2]. With ischemic stroke being the second leading cause of 
death and disability worldwide [3], there is a clear need for more effective therapies. As will be 
discussed below, emerging evidence suggests that ghrelin may be one such potential therapy.  
Ghrelin is a 28 amino acid peptide that is principally synthesized in the gut, but is also expressed in 
a variety of other tissues [4,5]. It was first identified in 1999 as a stimulator of growth hormone  
release [5]. Ghrelin exists in the plasma in a des-acylated and an acylated form, the latter of which is 
the result of post-translational octanoylation of pro-ghrelin by the enzyme ghrelin-O-acyltransferase 
(GOAT) [6]. Acylated ghrelin is the natural ligand of the growth hormone secretagogue receptor type 
1a (ghrelin receptor, GHS-R1a) through which growth hormone release is stimulated [5–7].  
Since this initial description, research has attributed many other functions to the peptide, including 
its well-known role in feeding and metabolism [8–11]. Under situations of food deprivation, acylated 
ghrelin signals through the hypothalamus to promote feeding and energy conservation [10,12]. Ghrelin 
also has a number of significant extra-hypothalamic neuronal functions, including in reward and 
motivation [13,14], learning and memory [15], and stress [16,17]. For instance, we have recently 
shown ghrelin attenuates the hypothalamic-pituitary-adrenal axis response to acute stress, probably by 
acting on the anterior pituitary to stimulate adrenocorticotropic hormone release and thus enhance 
glucocorticoid negative feedback [16].  
The GHS-R1a is expressed throughout the brain including in feeding and metabolism-associated 
areas like the arcuate nucleus (ARC) [18–20], as well as regions important in memory (Cornu 
Ammonis (CA)2, CA3, dentate gyrus of the hippocampus) and reward (ventral tegmental area, 
substantia nigra pars compacta (SNpc), dorsal raphe) [19,21,22]. The GHS-R1a is a g-protein coupled 
seven transmembrane receptor. Ghrelin activates the GHS-R1a leading to stimulation of the 
phospholipase C (PLC)/protein kinase C (PKC)/inositol trisphosphate (IP3) pathway that triggers  
IP3-dependent calcium release from intracellular stores. This intracellular calcium coupled with 
calcium entering the cell via voltage-gated L-type calcium channels stimulates the GHS-R1a’s 
downstream responses [23–25]. In addition to its ghrelin-dependent effects, the GHSR has high 
constitutive activity in the absence of the ligand [26]. It is also able to dimerize with other receptors 
such as the dopamine receptor subtype 2 to modulate dopamine signaling [27], and the melanocortin-3 
receptor to modulate melanocortin signaling [28]. Ghrelin itself is also able to cross the blood brain 
barrier [5,18,29,30], making the ligand and receptor ideally placed to play an integral role in these 
diverse functions. As discussed below, evidence now suggests ghrelin may also have a role in 
neuroprotection in the setting of neurodegenerative disease and ischemic injury. 
2. Ghrelin’s Role in Neuroprotection 
2.1. Parkinson’s and Alzheimer’s Diseases 
Evidence for a role for ghrelin in neuroprotection came initially from findings that the peptide is 
able to inhibit apoptosis in cardiomyocytes [31], and protect these cells from myocardial  
ischemia-reperfusion injury [32,33]. These findings have since been extended to a role for ghrelin in 
neuroprotection in Parkinson’s (PD) and Alzheimer’s (AD) diseases [34]. Thus, endogenous  
and exogenous ghrelin have been shown to protect dopamine neurons of the SNpc in a  
Brain Sci. 2013, 3  
 
346
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced mouse model of PD [35–37]. It also 
protects against dopamine depletion in the striatum [36]. In this PD model, ghrelin protects the brain 
by upregulating uncoupling protein 2 resulting in enhanced mitochondrial respiration and a reduction 
in reactive oxygen species production [36]. Ghrelin also reverses the pro-apoptotic effects of MPTP 
and enhances the firing rate of the dopamine neurons to enhance dopamine availability during 
degeneration [36]. Interestingly, recent evidence suggests ghrelin production may be reduced in PD 
patients [38], raising the possibility that a reduction in ghrelin-mediated neuroprotection may 
contribute to increased vulnerability of dopaminergic neurons.  
With respect to AD, it is also noteworthy that plasma levels of ghrelin naturally decrease with age 
(in AD and in age-matched non-dementia subjects) [39] but AD is further associated with reduced 
brain GHS-R1a levels and reduced levels of brain GOAT [40]. Exogenous ghrelin is able to rescue 
memory deficits in mice given amyloid beta oligomers into the hippocampus. It also reduces the 
amyloid beta oligomer-induced microgliosis and neuronal loss in this region, and prevents amyloid 
beta oligomer-associated synaptic degeneration [41]. In vitro, ghrelin is able to limit tau 
hyperphosphorylation and increase glucose uptake in hippocampal neurons via a mechanism that 
involves the phosphatidylinositol 3-kinase (PI3K)/Akt/glycogen synthase kinase-3 beta (GSK-3B) 
pathway [42]. 
2.2. Cerebral Ischemia 
2.2.1. Observations of Neuroprotection 
It is also now evident that ghrelin can be a powerful neuroprotective agent in experimental models 
of cerebral ischemia. One of the first studies in this field revealed synthetic ghrelin (GHS-hexarelin) 
reduces injury to the cerebral cortex, hippocampus, and thalamus after neonatal hypoxia-ischemia [43]. 
As with AD, the neuroprotective effect here is associated with phosphorylation of Akt and GSK3B, 
indicating the PI3K pathway is involved.  
Early studies using models of adult stroke examined the effects of exogenous ghrelin administered 
immediately after either forebrain or focal ischaemia-reperfusion injury. Thus, Liu and colleagues [44] 
found ghrelin given i.p. daily for three days after a transient ischemia-reperfusion injury (four vessel 
occlusion) in the rat significantly increased the number of surviving neurons in the CA1 region of the 
hippocampus and significantly decreased the number of TUNEL-positive neurons in this region. 
Exogenous ghrelin also improves neurological deficit, infarct size, and survival of cortical neurons in 
rodents after transient focal ischemia-reperfusion (middle cerebral artery occlusion; MCAO) [45,46]. 
Again, similar to in PD models, its mechanism of action appears to be inhibition of pro-apoptotic 
pathways [45,46]. These findings are crucial from a clinical perspective. As with PD and AD, ghrelin 
levels are reduced in clinical stroke populations. In particular, ghrelin levels have been reported to be 
lower in male patients after cardioembolic stroke compared with the healthy controls [47]. Given the 
apparent neuroprotective properties of ghrelin, restoring ghrelin levels after stroke is therefore likely to 
have significant beneficial outcomes. We also suggest measuring ghrelin levels after stroke could be 
used as a diagnostic tool to predict prognosis. 
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2.2.2. Mechanisms of Neuroprotection 
There are three principal types of cell death induced by cerebral ischemia and hypoxic injury; 
apoptosis, necrosis, and autophagy [48]. In cases of focal ischemia, such as with an MCAO in rodents, 
or a focal stroke in humans, the major mechanism of cell death within the ischemic core is necrosis, 
and this occurs immediately after the insult [49]. The more delayed cell death that occurs in the 
ischemic penumbra (3–24 h and beyond) occurs via principally apoptotic and autophagic  
mechanisms [49], against which ghrelin may be useful. In cases of global cerebral ischemia, such as 
occurs in the brain after a cardiac arrest, the principal mechanism of cell death appears to be  
necrosis [50], and ghrelin may be less useful in these cases. However, we should note there is likely 
considerable overlap between these mechanisms of cell death.  
Apoptosis is a mechanism of cell “suicide” that is regulated by specific signaling pathways and can 
occur by caspase-dependent and caspase-independent mechanisms [48]. Necrosis has been termed a 
“cellular catastrophe”, where the cell fails due to a deficiency of ATP. However, it now appears some 
necrotic events are a consequence of specific signaling pathways. Necroptosis is one example of a 
necrotic-type cell death process that is regulated by cell signaling [48,49]. Neuronal cell death after 
ischemia can also occur via autophagy (type II death); a cellular degradation process wherein the 
mitochondria remain intact and functional. Autophagy is a normal cellular process that is initially 
protective and can promote neuronal survival [51], but under extreme conditions degradation of 
macromolecules and organelles such as the Golgi apparatus, endoplasmic reticulum, and 
polyribosomes ensues [48].  
2.2.2.1. Ghrelin Protects against Apoptosis 
When a cell becomes sufficiently depleted of oxygen and nutrients, pro-apoptotic genes involved in 
cell death are activated. This activation leads to the stimulation of pro-apoptotic BAX and suppression 
of anti-apoptotic Bcl2. These proteins interact to regulate the permeability of the mitochondrial 
permeability transition pore [52–55]. When BAX is activated, cytochrome c is released from the 
mitochondria and interacts with Apaf-1 such that Apaf-1 forms a complex with pro-caspase 9, leading 
to activation of caspase-9 and -3. Mitochondrial dysfunction therefore plays an important role  
in cell survival. Evidence suggests ghrelin inhibits apoptotic mechanisms by activating the  
extracellular-signalling-regulated-kinase (ERK)1/2, mitogen-activated protein kinase, protein kinase 
A, and protein kinase C pathways [36,56]. The activation of these pathways is associated with reduced 
activation of BAX, an improved Bcl2/BAX ratio and suppression of apoptosis/improved cell survival 
(Figure 1). Ghrelin also suppresses apoptosis by increasing expression of mitochondrial uncoupling 
protein UCP2. UCP2 elevation effectively buffers production of reactive oxygen species, protecting 
the cell from oxidative stress and reducing apoptosis [36,57,58]. Protective increases in UCP2 with 
ghrelin have been observed in traumatic brain injury and PD models [36,58].  
In the MPTP model of PD, ghrelin reverses the reduced expression of Bcl2 and increased 
expression of BAX associated with the MPTP to improve the Bcl2/BAX ratio and prevent  
apoptosis [35]. Similarly, in the MCAO (focal) and four vessel occlusion (forebrain) models of 
ischemia reperfusion, ghrelin suppresses the increase in the pro-apoptotic gene, Par-4, associated with 
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the ischemia [44,59]. Ghrelin thus also improves the Bcl2/BAX ratio and inhibits cytochrome c release 
and caspase-3 activation [44,59]. The neuroprotective effects of ghrelin are also mediated by activation 
of PI3K/Akt. Stimulation of this pathway by ghrelin leads to phosphorylation and inactivation of  
GSK-3B and stabilization of beta-catenin [56,60]. Beta-catenin is then able to translocate to the 
nucleus and stimulate transcription of various cell survival factors [56]. 
Figure 1. Ghrelin inhibits apoptosis and protects against inflammation. Ghrelin stimulates 
extracellular-signalling-regulated-kinase (ERK)1/2, mitogen-activated protein kinase 
(MAPK), protein kinase A (PKA), and protein kinase C (PKC) pathways to reduce activation 
of BAX, improve the Bcl2/BAX ratio and thus suppress apoptosis and improve cell survival. 
Inset; ghrelin inhibits neutrophil, lymphocyte, and microglial activation to suppress  
pro-inflammatory cytokine production and the secretion of inflammatory neurotoxins. 
 
This anti-apoptotic role for ghrelin is also seen after other neurodegenerative insults. Ghrelin 
ameliorates the reduction of pAkt and Bcl2 and attenuates the increase in caspase-3 expression in the 
caecal ligation and perforation model of sepsis. This action leads to a reduced cognitive deficit in this 
model [61]. Ghrelin also improves central outcomes after traumatic brain injury, suppressing caspase-3 
expression and reducing cell death around the impact site [58]. In vitro studies also suggest an  
anti-apoptotic role for ghrelin, with ghrelin treatment of primary hypothalamic neurons inhibiting 
apoptosis after oxygen-glucose deprivation via rapid ERK1/2 activation [62].  
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2.2.2.2. Ghrelin’s Effects on Necrosis and Autophagy 
To our knowledge, unlike with apoptosis, there is no current evidence that ghrelin directly 
influences necrotic neuronal cell death. Ghrelin may protect against necrosis caused by persistent 
ischemia in musculoskeletal tissues, but it does so by up-regulating iNOS, which, in turn, improves the 
local microcirculation [63]. There is some evidence ghrelin may be able to encourage cell survival by 
stimulating autophagy in cardiomyocytes under simulated hypoxic conditions leading to a more 
efficient removal of damaged organelles and misfolded proteins [64]. However, this pathway has not 
yet been examined in vivo or in models of cerebral ischemia. Also, care must be taken with the 
interpretation of these results as extensive autophagy can be detrimental to the cell [48].  
2.2.2.3. Acylated versus Des-Acylated Ghrelin 
It is interesting that ghrelin appears to be neuroprotective somewhat independently of acylation 
state [56]. Both ghrelin forms have been reported to prevent cell death and apoptosis in cultured 
neurons exposed to oxygen and glucose deprivation (an in vitro model of ischemia) [56,62], suggesting 
the neuroprotective actions of ghrelin in vivo are likely to occur through direct effects on neurons and 
independently of growth hormone release. Both acylated and des-acylated ghrelin also protect cortical 
neurons after transient focal ischemia-reperfusion (MCAO). In both cases, ghrelin can prevent 
apoptosis by suppressing the increase in expression of the pro-apoptotic gene Par-4 [56]. Acylated and 
des-acylated ghrelin also both improve the Bcl2/BAX ratio, and inhibit cytochrome c release and 
caspase-3 activation [59]. While it is clear the effects of acylated ghrelin are mediated by the  
GHS-R1a [56,59], des-acylated ghrelin does not activate GHS-R1a [34], and its neuroprotective 
effects are unaffected by the GHS-R1a antagonist D-Lys-3-growth hormone releasing peptide  
(GHRP)-6 [56]. The receptor through which des-acylated ghrelin mediates its neuroprotective effects 
remains to be determined. The GHS-R1a is certainly important for ghrelin’s neuroprotective actions, 
however. For example, in the MPTP model of PD, both ghr−/− and GHSR−/− mice have greater loss 
of dopamine neurons in the SNpc than wild type mice [36]. Similarly, expression of the GHS-R1a is 
reduced in the brain [45] and spinal cord [65] by ischemia-reperfusion and exogenous ghrelin 
treatment is able to reverse this effect, leading to an improved Bcl2/BAX ratio [45]. Of potential 
importance, the GHS-R1a has considerable constitutive activity in the absence of the ligand [26] and 
may significantly contribute to limiting apoptosis after ischemia even when ghrelin is low.  
2.2.2.4. Ghrelin Protects against Inflammation 
In the hours to days after an ischemic event, the degree of inflammation plays a significant role in 
the severity of the injury [66]. In the early stages of ischemia-reperfusion, neutrophils and lymphocytes 
are recruited to the injury site and these are mostly neurotoxic, secreting inflammatory mediators such 
as cytokines and contributing to brain injury [67]. Microglia and astrocytes are then activated and 
secrete pro-inflammatory cytokines and other factors, such as inducible nitric oxide synthase (iNOS), 
that are also cytotoxic [68]; although microglia also play a protective role in removing cytotoxic debris 
at some stages of the inflammation [66,69].  
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Another mechanism by which ghrelin may improve cell survival after ischemia is therefore by 
suppressing inflammation (Figure 1). Exogenously applied ghrelin successfully suppresses inflammation 
in many models of pathology, including sepsis [70], non-alcoholic fatty liver disease [71], burn-induced 
multiple organ injury [72], traumatic brain injury [73], and ischemia [46]. For instance, after 
subarachnoid haemorrhage, ghrelin can suppress the release of the pro-inflammatory cytokines tumour 
necrosis factor (TNF)α and interleukin (IL)-1β to improve outcomes [74]. Ghrelin suppresses TNFα 
and IL-6 induced by traumatic brain injury [73]. Likewise, ghrelin reduces the serum TNFα and 
myeloperoxidase activity induced by ischemic-reperfusion spinal cord injury [65]. 
Ghrelin’s neuroprotective role in PD is partially due to its anti-inflammatory effects. Thus, ghrelin 
is able to reduce MPTP-associated microglial activation in the SNcp and striatum as well as reduce the 
expression of TNFα, and IL-1β mRNA, and iNOS activation in the ventral midbrain to improve 
neuronal survival in these regions [37]. These anti-inflammatory effects are potentially  
GHS-R1a-mediated (i.e., due to acylated ghrelin and not des-acylated ghrelin) as the antagonist,  
D-Lys-3-GHRP-6, attenuates the effect [37]. 
Ghrelin also extends this anti-inflammatory function to cerebral ischemia-reperfusion injury. 
Ghrelin treatment in rats after an MCAO reduced MCAO-induced neutrophil trafficking, TNFα, IL-6, 
matrix metalloproteinase 9, and nNOS, as well as apoptosis [46]. This treatment was associated with 
reduced infarct size, reduced neurological deficit, and improved 7-day survival. In this case it appears 
ghrelin’s mechanism of action is at least partially vagally mediated, as prior vagotomy blunted this 
neuroprotective effect [46]. A role for the vagus has also been suggested for ghrelin’s action in 
traumatic brain injury [75]. Ghrelin, thus, may be useful as an anti-inflammatory agent in cases of 
neurodegenerative disease.  
3. Clinical Considerations 
Experimental evidence in animal models clearly suggests ghrelin may be a useful therapeutic after 
cerebral ischemia. This role may prove to be all the more crucial when we consider the ghrelin system 
appears to be altered in the setting of known stroke risk factors such as aging, obesity, and 
hypertension. For example, during the normal aging process there is a reduction in the sensitivity to the 
metabolic effects of ghrelin [76–78]. This insensitivity may be compounded by an aging-related 
decline in circulating ghrelin levels [39]. Obesity is associated with a central resistance to the 
metabolic effects of ghrelin [79], and ghrelin levels are reduced in obese and overweight humans [80]. 
Similarly, low ghrelin levels have also been reported to be independently associated with the 
development of type two diabetes and elevated blood pressure [81], and the Arg51Gln (rs34911341) 
single-nucleotide polymorphism of ghrelin is linked to an increased risk of hypertension, and is 
associated with low ghrelin levels [82]. Circulating ghrelin is also lower in patients who have 
experienced stroke than in the general population when controlling for factors such as age and  
obesity [47]. Collectively, these findings raise the intriguing possibility that low ghrelin levels per se 
may be a risk factor for stroke, and imply that ghrelin might not only be an effective intervention 
therapy after a stroke has occurred, but also an approach to prevent a stroke from occurring in the first 
place. There is therefore a strong rationale to evaluate whether increasing ghrelin levels and/or 
improving sensitivity to circulating ghrelin during aging is an effective strategy to prevent ischemic 
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stroke damage. Of importance, experimental evidence indicates ghrelin can influence the sensitivity of 
the brain to its actions [62,83]. Specifically, studies have shown that GHS-R1a expression in the brain 
is increased following either central or peripheral administration of ghrelin to rodents [62,83]. Thus, 
sensitivity to circulating ghrelin could be improved during stroke risk factors (and after stroke) by 
“simply” increasing circulating ghrelin levels through ghrelin supplementation.  
An important consideration with using ghrelin as a therapeutic is the timing of the dose. As 
suggested, restoring normal ghrelin levels in aging or other populations where ghrelin is low may be a 
viable therapy, and in this case chronic ghrelin treatment would be necessary. An alternative strategy is 
to employ a single or repeated supra-physiological dose as a therapeutic agent and the vast majority of 
preclinical studies have tested single doses of exogenous ghrelin at the time of injury (Table 1). 
Unfortunately, this is likely to be effective only in the 30 min or so after administration, as ghrelin’s 
half-life is very short (approximately 25–30 min in humans [84,85]). As such, a single dose at this time 
would likely influence early apoptosis and inflammation, but not affect the ongoing ischemic injury. 
Since brain damage after ischemic injury can continue to worsen for hours to days and weeks after the 
event depending upon the type of injury [86], chronic ghrelin treatment may be more appropriate after 
injury as well as a prophylaxis. In either case, such treatments need to be considered carefully and 
further research is needed. For instance, studies have shown glutamatergic neurotransmission is 
necessary for ghrelin’s effects on mesolimbic dopaminergic reward pathways [87] and that ghrelin 
stimulates memory formation in a glutamate-dependent manner [15]. However, excessive glutamate 
release can lead to excitotoxicity [88], which would obviously be detrimental after ischemic injury. 
The circadian timing of the ghrelin administration must also be considered, as evidence from the PD 
model suggests exogenous ghrelin may only be effective if the subject is fasted [36].  
When evaluating the overall usefulness of ghrelin as a therapeutic for cerebral injury after ischemia, 
it is also important to consider the potential long-term consequences on body homeostasis. For 
example, exogenous acylated ghrelin would be expected to act at the GHS-R1a to stimulate appetite, 
food intake, and weight gain. While this may be a problem in the general population, it may actually 
be of benefit in those recovering from stroke as weight loss after stroke has been linked with a worse 
long-term prognosis [89]. Thus, ghrelin as a stroke therapy could have an additional beneficial effect 
by preventing age-related malnutrition and frailty, as well as weight loss after stroke. An alternative 
option in those where weight gain is a concern is also to employ the des-acylated form of ghrelin.  
Des-acylated ghrelin does not act at GHS-R1a and does not have the same metabolic effects as the 
acylated form. It is, however, effective at preventing neurodegeneration and improving outcomes after 
ischemic damage [56]. Further research will be necessary to determine its mechanism of action and 
effects on other neuronal functions such as reward and stress, but treatment with des-acylated ghrelin 
is nonetheless a useful potential option. 
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Table 1. Effects, and associated mechanisms, of ghrelin on outcomes after cerebral ischemia. All studies were conducted in rats except where 
indicated. Arrows are relative to vehicle-treated ischemic groups. 
Ischemic injury Dose Timing Effect Mechanism of action  Reference 
Oxygen-glucose deprivation in 
cultured cells 
Acylated and unacylated 
ghrelin, 100 nM each 
Pretreatment for 24 h ↓ cell death (both)  ↓ apoptosis  [56,62] 
Doxorubicin H9c2 
cardiomyocytes 
Total ghrelin, 1 µM Co-treatment for 24 h ↓ cell death (both) ↓ apoptosis  
GHSR-1a-independent 
mechanism  
[31] 
4VO  
forebrain ischemia/reperfusion 
Total ghrelin, i.p., 0.4 mg/kg Daily for 3 days post injury ↑ cell survival CA1 hippocampus ↓ apoptosis [44] 
MCAO 
Focal ischemia/reperfusion 
Total ghrelin, i.v., 10 pmol/kg Immediately post injury ↓cortical neuron injury ↓ apoptosis  
↑ expression of GHSR-1a 
[45] 
MCAO Total ghrelin, i.v., ~7 pmol/kg  Immediately post injury 
infusion for 1 h 
↓ neurological deficit,  
↓ infarct size at 24 h and 7 days 
↓ apoptosis  
↓ inflammation  
[46] 
MCAO Total (80 µg/kg) or desacyl 
(160 µg/kg), i.p. 
30 min prior to injury and 
immediately post 
↓ cortical neuron injury (both) ↓ apoptosis  
GHSR-1a-independent 
mechanism 
[59] 
Neonatal hypoxia-ischemia GHS-hexarelin, icv,  
1 µg in 5 µL  
Immediately post injury ↓ cortical, hippocampal, thalamic 
injury, ↔ striatum 
↓ apoptosis [43] 
Spinal cord 
ischemia/reperfusion 
Total ghrelin, i.p., 100 µg/kg Ischemia onset ↑ neurological scores ↓ apoptosis  
↓ inflammation 
↑ expression of GHSR-1a 
[65] 
Subarachnoid hemorrhage Total ghrelin, i.p.,  
10 µg/kg/day 
Immediately post injury and  
24 h later 
↑ neurological scores  ↓ inflammation [74] 
Traumatic brain injury Total ghrelin, i.v.,  
4, 8 or 16 nmol/rat 
45 min post-injury ↓ cortical neuron injury 
↓ behavioural deficits 
↓ apoptosis  
↓ inflammation 
[73] 
Traumatic brain injury Total ghrelin, i.p.,  
10 µg/kg/dose 
Immediately prior to and 1 h 
post injury 
↓ cell death  ↓ inflammation  
↓ blood brain barrier 
permeability 
[58] 
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4. Conclusions 
The research reviewed here suggests the peptide hormone, ghrelin, may be an exciting novel 
candidate in our search for treatments for ischemic brain injury. It is clear ghrelin treatment can provide 
significant neuroprotection in a number of models of neurodegenerative disease and following ischemic 
brain injury. Indeed, ghrelin is effective in improving cell survival, reducing infarct size and rescuing 
memory in these models. It does this primarily by suppressing the apoptosis and inflammation associated 
with the ischemic injury. However, it remains to be determined whether ghrelin also modulates necrotic 
or autophagic mechanisms of cell death. Nonetheless, these exciting data collectively point to ghrelin 
potentially being very useful in the clinic as a neuroprotective treatment.  
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